Wedbush Decreases Earnings Estimates for Ovid Therapeutics

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities researchers at Wedbush lowered their Q2 2025 earnings estimates for shares of Ovid Therapeutics in a report issued on Tuesday, May 13th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.13). Wedbush has a “Outperform” rating and a $3.00 price target on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.23) EPS and FY2029 earnings at ($0.32) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.03 million. Ovid Therapeutics had a negative net margin of 5,142.56% and a negative return on equity of 39.24%.

Several other equities analysts have also recently weighed in on OVID. BTIG Research dropped their price objective on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Monday, March 24th. Oppenheimer raised shares of Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research report on Wednesday, January 29th. Finally, William Blair raised shares of Ovid Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $3.03.

Ovid Therapeutics Stock Performance

Shares of Ovid Therapeutics stock opened at $0.31 on Friday. Ovid Therapeutics has a 52 week low of $0.24 and a 52 week high of $3.41. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.18. The business has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.70. The company has a market cap of $21.71 million, a PE ratio of -0.65 and a beta of 0.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OVID. Rhumbline Advisers raised its holdings in shares of Ovid Therapeutics by 22.3% in the 4th quarter. Rhumbline Advisers now owns 84,078 shares of the company’s stock worth $79,000 after purchasing an additional 15,355 shares during the period. SG Americas Securities LLC raised its stake in shares of Ovid Therapeutics by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after buying an additional 17,172 shares during the period. Kennedy Capital Management LLC raised its stake in shares of Ovid Therapeutics by 1.1% in the fourth quarter. Kennedy Capital Management LLC now owns 1,545,387 shares of the company’s stock valued at $1,443,000 after buying an additional 17,402 shares during the period. Bank of America Corp DE lifted its position in shares of Ovid Therapeutics by 49.7% during the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after buying an additional 18,841 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Ovid Therapeutics by 142.0% during the 4th quarter. Renaissance Technologies LLC now owns 107,700 shares of the company’s stock worth $101,000 after acquiring an additional 63,200 shares during the period. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.